Tifcemalimab (JS004) is a humanised antibody targeting BTLA (B and T lymphocyte attenuator), which binds to BTLA and blocks the interaction between HVEM and BTLA, exhibiting immunomodulatory and antitumour activity.
Purity:
95.00%
CAS Number:
[2236068-83-8]
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted